J. Scott Wolchko

J. Scott Wolchko

President, Chief Executive Officer, Chief Financial Officer and DirectoratFate Therapeutics· In proxies 2022–2024

Pay in FY2024+19% from the year before · Fate Therapeutics stock -55.9% the same year

J. Scott Wolchko was paid $4.2M in FY2024 (Dec), up 19%. Fate Therapeutics stock fell 55.9% that year.

Pay$100 in the stock at the end of FY21 → $3
Pay is from the Summary Compensation Table of each Fate Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Fate TherapeuticsPublic company · 4 yr
    • President, Chief Executive Officer, Chief Financial Officer and Director2022 – Present · 4 yrStock in role -96%

Roles come from the proxy statements of each company.

Activity

Two people shown as one, or a wrong number?